Abstract
Based on the first favourable results of adjuvant therapy of 5FU plus levamisole in Dukes C colonic cancer in 1990, we conducted a prospective trial. 1029 patients were randomised to receive one year 5FU plus levamisole or no further treatment following curative surgery for stage II or III colon (n = 730) or rectal cancer (n = 299). 45% were in stage II and 55% in stage III. With a median follow-up of 4 years and 9 months a significant reduction in odds of death (25%, SD 9%, P = 0.007) was observed for those with adjuvant treatment (65% at 5 year) compared to the observation group (55%). Improved relative survival was present in stage III (56% vs 44%), and in stage II patients (78% vs 70%). In rectal cancer a non-significant difference in disease-free or overall survival was observed. Distant metastases developed in 76%, while local recurrence alone occurred in 14%. An early start of adjuvant treatment (< 4 weeks) did not affect results. Compliance to 5FU plus levamisole was 69%. Severe toxicity did not occur. In conclusion, one year 5FU plus levamisole was of benefit in stage II and III colonic cancer; in rectal cancer a significant positive effect could not be demonstrated. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Buyse M, Zeleniuch-Jacqoutte A and Chalmers TC (1988) Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA 259: 3571–3578
Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerman DL, Fisher ER, Caplan R, Jones J, Lerner H, Gordon P, Feldman M, Cruz A, Legault-Poisson S, Wexler M, Lawrence W and Robidoux A (1988) Postoperative adjuvant therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 80: 21–29
Frykholm GJ, Glimelius B and Pahlman L (1993) Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomised trial and an evaluation of late secondary effects. Dis Colon Rectum 36: 564–572
International Multicentre Pooled analysis of colon cancer trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939–944
International Multicentre Pooled analysis of B2 colon cancer trials (IMPACT B2) investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356–1363
Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, Twito DI, Morton RF, Veeder MH, Witzig TE, Cha S and Vidyarthi SC (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324: 709–715
Laurie JA, Moertel CG, Fleming TR Wieand S, Leigh JE, Rubin J, McCormack W, Gerstner JB, Krook JE, Mailiard J, Twito DI, Morton RF, Tschetter K and Barlow JF (1989) Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil: the North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447–1456
Mamounas EPet al, Rochette H, Jones J, Wieand S, Wickerman DL, Fisher B and Wolmark N (1997) Comparitive efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: results from four NSABP adjuvant studies (CO1, CO2, CO3, CO4). J Clin Oncol 16: 205
Marijnen CAM, Nagtegaal ID, Klein Kranenborg E, Hermans J, Van de velde CJH, Leer JWH and Van Krieken JHJM (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19: 1976–1984
Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Maillard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352–358
Moertel CG, Fleming TR and MacDonald JS (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321–326
NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444–1450
O’Connell M, Maillard JA, Kahn MJ, Mac Donald JS, Haller DG, Mayer RJ and Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: 246–250
O’Connell M, Laurie JA, Kahn MJ, Fitzgibbons RJ, Erlichman C, Shepherd L, Moertel CG, Kocha R, Pazdur R, Wieand HS, Rubin J, Vukow AM, Donohue J, Krook JE and Figueredo A (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295–300
Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336: 980–987
Treurniet-Donker AD, van Putten WJL, Wereldsma JCJ, Bruggink EDM, Hoogenraad WJ, Ronkema JA, Snijders-Keilholz A, Meijer WS, Meerwaldt JH, Wijnmalen AJ and Wigger TH (1991) Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective multicenter trial in the Netherlands. Cancer 67: 2042–2048
Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jone J, Mamounas EP, Ore L, Peterli N, Spurr CL, Dimitrov N, Romond EH, Surthrtland CM, Kardinal CG, Defusco P and Jochimsen P (1993) Benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Protocol C-03. J Clin Oncol 11: 1879–1887
Wolmark N, Rockette H and Mamounas EP (1999) Clinical trial to assess the relative efficacy of Fluorouracil and leucovorin, Fluorouracil and levamisole, and Fluorouracil, leucovorin, and levamisole in patients with Dukes’B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17: 3553–3559
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Taal, B., Van Tinteren, H., Zoetmulder, F. et al. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 85, 1437–1443 (2001). https://doi.org/10.1054/bjoc.2001.2117
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2117
Keywords
This article is cited by
-
Development of a novel prediction model for recurrent stage II colon cancer
Surgery Today (2020)
-
Alkaline phosphatase: a potential biomarker for stroke and implications for treatment
Metabolic Brain Disease (2019)
-
Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study
World Journal of Surgery (2016)
-
Solitary lymph node metastasis is a distinct subset of colon cancer associated with good survival: a retrospective study of surveillance, epidemiology, and end-results population-based data
BMC Cancer (2014)
-
Lymph node metastasis of carcinomas of transverse colon including flexures. Consideration of the extramesocolic lymph node stations
International Journal of Colorectal Disease (2014)